



Universiteit
Leiden
The Netherlands

Application of machine learning to predict tacrolimus exposure in liver and kidney transplant patients given the MeltDose formulation

Ponthier, L.; Marquet, P.; Moes, D.J.A.R.; Rostaing, L.; Hoek, B. van; Monchaud, C.; ... ; Woillard, J.B.

Citation

Ponthier, L., Marquet, P., Moes, D. J. A. R., Rostaing, L., Hoek, B. van, Monchaud, C., ... Woillard, J. B. (2022). Application of machine learning to predict tacrolimus exposure in liver and kidney transplant patients given the MeltDose formulation. *European Journal Of Clinical Pharmacology*, 79, 311-319. doi:10.1007/s00228-022-03445-5

Version: Not Applicable (or Unknown)

License: [Licensed under Article 25fa Copyright Act/Law \(Amendment Taverne\)](#)

Downloaded from: <https://hdl.handle.net/1887/3515277>

Note: To cite this publication please use the final published version (if applicable).



Application of machine learning to predict tacrolimus exposure in liver and kidney transplant patients given the MeltDose formulation

Laure Ponthier^{1,2} · Pierre Marquet^{1,3} · Dirk Jan A. R. Moes⁴ · Lionel Rostaing⁵ · Bart van Hoek⁶ · Caroline Monchaud^{1,3} · Marc Labriffe^{1,3} · Jean Baptiste Woillard^{1,3}

Received: 4 October 2022 / Accepted: 15 December 2022 / Published online: 24 December 2022
© The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature 2022

Abstract

Purpose Machine Learning (ML) algorithms represent an interesting alternative to maximum a posteriori Bayesian estimators (MAP-BE) for tacrolimus AUC estimation, but it is not known if training an ML model using a lower number of full pharmacokinetic (PK) profiles (= “true” reference AUC) provides better performances than using a larger dataset of less accurate AUC estimates. The objectives of this study were: to develop and benchmark ML algorithms trained using full PK profiles to estimate MeltDose®-tacrolimus individual AUCs using 2 or 3 blood concentrations; and to compare their performance to MAP-BE.

Methods Data from liver ($n = 113$) and kidney ($n = 97$) transplant recipients involved in MeltDose-tacrolimus PK studies were used for the training and evaluation of ML algorithms. “True” AUC_{0-24 h} was calculated for each patient using the trapezoidal rule on the full PK profile. ML algorithms were trained to estimate tacrolimus true AUC using 2 or 3 blood concentrations. Performances were evaluated in 2 external sets of 16 (renal) and 48 (liver) transplant patients.

Results Best estimation performances were obtained with the MARS algorithm and the following limited sampling strategies (LSS): predose (0), 8, and 12 h post-dose (rMPE = − 1.28%, rRMSE = 7.57%), or 0 and 12 h (rMPE = − 1.9%, rRMSE = 10.06%). In the external dataset, the performances of the final ML algorithms based on two samples in kidney (rMPE = − 3.1%, rRMSE = 11.1%) or liver transplant recipients (rMPE = − 3.4%, rRMSE = 9.86%) were as good as or better than those of MAP-BEs based on three time points.

Conclusion The MARS ML models developed using “true” MeltDose®-tacrolimus AUCs yielded accurate individual estimations using only two blood concentrations.

Keywords Machine learning · Population pharmacokinetics · Tacrolimus MeltDose · Transplantation · Model informed precision dosing

What is already known about this subject:

- Machine learning (ML) algorithms are an interesting alternative to maximum a posteriori Bayesian estimators (MAP-BE) for tacrolimus AUC estimation.
- It is not known if training an ML model using a lower number of full pharmacokinetic (PK) profiles (= “true” reference AUC) provides better performances than using a larger dataset of less accurate AUC estimates.

What this study adds:

- ML algorithms were trained from liver ($n = 113$) and kidney ($n = 97$) transplant recipients involved in MeltDose-tacrolimus PK studies in whom the reference AUC_{0-24 h} was calculated using the trapezoidal rule on the full PK profiles.
- External validation showed that the performances of the final ML algorithms (MARS) based on two samples were as good as or better than those of MAP-BEs based on three time points.
- The performances in an external validation set obtained in the present study were similar to and no better than those obtained using a larger dataset of less accurate AUC estimates.

Introduction

Tacrolimus is a calcineurin inhibitor very frequently employed in the prevention and treatment of allograft rejection in solid organ transplantation. It exhibits a narrow therapeutic index and a large interindividual and long-term intraindividual variability, making therapeutic drug monitoring and individual dose adjustment essential [1, 2]. Several factors influence its pharmacokinetics and explain part of this inter or intra-individual variability, such as patient age, drug-drug or drug-food interactions, genetic polymorphisms of CYP3A isoenzymes, hematocrit, and serum albumin concentration [3].

Therapeutic drug monitoring (TDM) helps to prevent or correct overexposure that may increase the risk of adverse effects as well as underexposure that may increase the risk of allograft rejection [4]. In routine care and as recommended

Extended author information available on the last page of the article

in the Summary of Product Characteristics, tacrolimus TDM and dose adjustment for all available formulations are performed using trough concentration (C_0) [1, 2]. Indeed, C_0 is a surrogate of the area under the concentration–time curve (AUC) as it exhibits a good but variable correlation [5]. However, AUC seems to be a more precise marker of exposure and has been associated with tacrolimus efficacy/safety [6, 7]. One of the limits of the use of AUC is that it requires collecting a relatively large number of blood samples.

Envarsus® is a prolonged-release, once-daily formulation of tacrolimus developed by Veloxis using their patented technology MeltDose® (Veloxis Pharmaceuticals, Hørsholm, Denmark). Population pharmacokinetic (POPPK) models and maximum a posteriori Bayesian estimators (MAP-BE) were developed for Envarsus®. They allow for AUC estimation based on a three-point limited sampling strategy (LSS): predose (0), 8, and 12 h post-dose, one model for kidney and one for liver transplantation [8], or 0, 4, and 8 h in liver transplant recipients [9].

Machine learning (ML) techniques [10] can also be used to estimate the AUC of immunosuppressive drugs based on patient features and observed concentrations. ML encompasses several methods (e.g., support vector machine (SVM), partial least squares discriminant analysis (PLS-DA), random forest, boosting, multivariate adaptive regression splines (MARS), etc.) that involve complex algorithmic designs, including large numbers of free parameters and complex interactions, to minimize errors between predicted and observed values by means of an error function.

Recently, Woillard et al. trained Xgboost (extreme gradient boosting) machine learning (ML) algorithms to estimate immediate release tacrolimus AUC using only two blood concentrations (0 and 3 h) [11]. These algorithms were trained from very large numbers of requests gathered on a web platform where the reference AUC was estimated using a 3-point LSS and MAP-BE (<https://abis.chu-limoges.fr/login>). In this case, the “reference” AUC corresponded to the real AUC value + uncertainty (“noise”) due to MAP-BE estimation. It is possible that training ML algorithms with a smaller dataset of more accurate “true” AUCs (calculated from rich concentration–time profiles using the trapezoidal rule for instance) would yield a good or even improved performance.

The objectives of this study were: (i) to train ML algorithms on a dataset of MeltDose®-tacrolimus full PK profiles to estimate individual AUCs using only 2 or 3 blood concentrations and (ii) to compare their performance to those of MAP-BE with the LSSs 0, 8, and 12 h or 0, 4, and 8 h in independent sets of patients.

Material and methods

Patients

Clinical and pharmacokinetic data from 113 liver and 97 kidney transplant patients from two phase II, open-label, multicenter prospective US clinical trials conducted on stable adult kidney and liver transplant patients who were converted from Prograf® capsules twice daily to Envarsus® (MeltDose®-tacrolimus) tablets once daily were used for training and testing ML algorithms. These trials complied with the Declaration of Helsinki amended in Tokyo, and all the patients enrolled gave their written informed consent. These data have been previously used to develop a POPPK and derive a MAP-BE based on LSS [8]. Briefly, all patients transplanted for at least 6 months were switched from Prograf® to Envarsus® on day 8 of the study and had two PK assessments on days 14 and 21. For each patient, 13 blood samples were collected pre-dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 20, and 24 h after dosing. All samples were measured using a validated liquid chromatography-tandem mass spectrometry method with a lower limit of quantitation of 0.2 ng/ml.

The “true” AUC was calculated for each patient using the trapezoidal rule on the full PK profiles in the PKNCA R package [12].

Preparation of the data and feature engineering

Concentrations and sampling times were extracted and binned into theoretical time classes: concentrations at 0 (“C0” sampled at $t=0$ min), 1 h (“C1” sampled between 0.7 and 1.1 h), 2 h (“C2,” 1.6–2.5 h), 3 h (“C3,” 2.6–3.5 h), 4 h (“C4,” 3.6–4.5 h), 6 h (“C6,” 4.6–6.5 h), 8 h (“C8,” 6.6–8.5 h), 12 h (“C12,” 8.6–12.5 h), 20 h (“C20,” 16.6–20.6 h), and 24 h (“C24,” 20.7–25.5 h). The range of the time classes was investigated and selected manually in order to have every time represented in each patients. When relevant, deviation from the theoretical sampling times was taken into account by creating a new variable corresponding to the relative deviation with respect to the theoretical time in each bin.

Finally, AUC prediction was attempted based on 2 or 3 concentrations, the relative time deviation and other predictors including demographic data (age, sex, time elapsed since transplantation, transplanted organ (liver or kidney), and hematocrit). The individual status regarding cytochrome P450 3A5 polymorphisms was not known in the original study and could not be investigated further.

Machine learning analysis

All pre-processing and machine learning analyses were performed using the tidymodels framework in R version 4.0.5 [13]. Missing concentration data were imputed using the k nearest neighbors (with $k=5$). Data splitting between a training set (75%) and a test set (25%) was performed by random selection of patients. The training set was secondarily split into an analysis set (80%) and an assessment set (20%) in order to benchmark different ML algorithms and select the best without wasting the test set for this purpose. Preprocessing consisted of normalization (centering and scaling) of numeric variables and one hot encoding of categorical features.

Xgboost [14], MARS [15], and GLMNET (generalized linear model via penalized maximum likelihood) [16] algorithms with different combinations of three concentration–time points were first trained and compared based on the root mean square error (RMSE) and coefficient of determination (R^2). The combinations investigated were 0/8/12 h, 0/2/6 h, 0/2/4 h, 0/4/6 h, 0/4/8 h, 0/2/12 h, and 0/6/12 h based on previous studies [8, 9].

The combination of C0 with the 2 most important concentration–time points in variable importance plots was then investigated for the development of ML algorithms based on 2 points, and the selection was based on performance (RMSE).

For each algorithm and combination, the hyperparameters were tuned using ten-fold cross-validation in the analysis set. Once optimized, ML algorithms were evaluated in the assessment set to select the best in terms of prediction performance. The best algorithm was refined using the analysis and assessment sets combined and was finally evaluated in the test set. The global procedure is summarized in Supplemental Fig. 1.

External evaluation and comparison with other approaches

The final ML algorithms based on 2 or 3 concentrations were evaluated in two external, independent datasets in which tacrolimus was measured using validated liquid chromatography–tandem mass spectrometry methods.

The first comprised 16 full PK profiles (13 blood samples collected at pre-dose and 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 13, 15, and 24 h after dosing) of MeltDose[®]-tacrolimus from stable renal transplant patients. The performances of the different ML algorithms were compared to those of 2 MAP-BE using two different 3-point LSSs: 0/8/12 h, intended for renal transplant patients [8], and 0/4/8 h, intended for liver transplant patients [9]. The reference AUC was calculated using the trapezoidal rule on all the available samples.

The second external set comprised data from 51 stable liver transplant patients at 2 weeks after conversion (9 blood

samples collected at pre-dose and 1, 2, 3, 4, 6, 8, 12, and 24 h after dosing), used to develop the POPPK model and the MAP-BE based on the 0/4/8 h LSS [9]. Three patients with sampling time deviation > 5% or 1 h from the theoretical LSS were excluded from the analysis. In this dataset, the reference AUC was obtained by application of the POPPK model and the MAP-BE on the 9 samples. The different ML algorithms were compared to MAP-BE using the 0/8/12 h LSS [8] and to the results reported in the original study in liver transplant patients [9].

Results

Data

Two hundred ten PK profiles were available in the original dataset and were randomly assigned to the training ($n=158$) or test ($n=52$) set. In the original dataset used for the development of the ML algorithm, the proportion of imputed data was 0% for C0, 2.3% for C0.5, 1.9% for C1, 1.4% for C1.5, 1.4% for C2, 0.95% for C3, 0.95% for C4, 0% for C6, 1.4% for C8, 0.5% for C12, 0.5% for C16, 0.95% for C20, and 0% for C24. In the training set, 130 were randomly assigned to the analysis and 28 to the assessment set. In one of the external datasets, among the 51 PK profiles from liver transplant recipients, only 48 had concentrations at 0, 8, and 12 h available. Patient characteristics in the training, assessment, test sets, and in the 2 external validation sets are provided in Table 1.

Comparison of algorithms

The results obtained with each ML algorithm and the different 3-point combinations showed, as previously observed [8], that the 0/8/12 h LSS was always associated with the best performances in the assessment set (Supplemental Table 1). While GLMNET displayed slightly better results in the analysis set, the MARS algorithm yielded the best performances in the assessment set (relative RMSE = 7.57%, relative MPE = −1.28%) followed by Xgboost (relative RMSE = 9.17%, relative MPE = 0.43%) and GLMNET (relative RMSE = 10.12%, relative MPE = 0.90%) (Table 2). Figure 1 shows the scatter plot and Bland–Altman plot of the individually predicted vs reference AUC0–24hs for the 0/8/12 h LSS in the test set with the MARS algorithm.

The variable importance plot for the MARS algorithm showed that the concentrations at 8, 12, and 0 h were the most important, in this order (Fig. 2), leading us to investigate different combinations of the 3 concentration–time points for the 2-point ML algorithms.

Table 1 Patient characteristics in the analysis, assessment, train, test, and external sets

Variables	Analysis set <i>N</i> = 130	Assessment set <i>N</i> = 28	Training set (analysis + assessment set) <i>N</i> = 158	Test set <i>N</i> = 52	External set Renal <i>N</i> = 16	External set Liver <i>N</i> = 48
Age (years)	49 (11)	47 (11)	49 (11)	48 (12)	49 (16)	54 (12)
Daily dose (mg)	5.0 (3.0)	3.6 (1.7)	4.8 (2.9)	5.2 (3.0)	4.2 (2.4)	2.5 (1.5)
Sex: male (%)	82 (63.1%)	14 (50.0%)	96 (60.8%)	36(69.2%)	9 (56.2%)	35 (68.6%)
Hematocrit (%)	40.7 (4.8)	40.2 (3.7)	40.7 (4.6)	39.8 (4.6)	40.4 (4.3)	40.6 (4.5)
AUC _{0–24} (μg·h/L)	207 (74.)	209 (61)	207 (73)	205 (53)	202 (78)	152 (66)
Liver <i>n</i> (%)	68 (52.31%)	19 (67.86%)	87 (100.00%)	26 (50%)	0 (0%)	48 (100%)
Kidney <i>n</i> (%)	62 (47.69%)	9 (32.14%)	71 (100.00%)	26 (50%)	16 (100%)	0 (0%)
Concentration at 0 h	6.2 (2.3)	6.4 (2.1)	6.2 (2.3)	6.3 (2.1)	6.3 (2.2)	5.0 (2.1)

Continuous variables are presented as mean (SD) and categorical variables as *n* (%)

Performances of the 2-point limited sampling strategies

The 2-point LSSs with concentrations measured at time 0 and 12 h performed best (Supplemental Table 2). The achievements of the different ML algorithms with this 0/12 h LSS in the analysis and assessment sets are compared in Table 2. The MARS algorithm again performed best and was therefore the only one evaluated in the test set, showing rMPE/rRMSE/number (%) out of the $\pm 20\%$ interval of $-0.36/10.4/2$ (3.8%), as compared to $1.62/9.8/5$ (9.4%) with the 3-point LSS. The scatter plot and Bland–Altman of predicted vs reference AUCs with the MARS algorithm and 2-point LSS in the test set are presented in Fig. 1.

Evaluation in external datasets


The results of the final MARS algorithm based on 2 or 3 points and of the MAP-BEs based on 3 points in both validation sets are compared in Table 3. The MARS algorithms with 2 points: (i) displayed similar performances to that with 3 points, the two independent datasets, of kidney and liver transplant recipients respectively; (ii) had a lower MPE than MAP-BE in kidney transplant patients, (iii) showed a RMSE almost half of that of the MAP-BE based on the 0/8/12 h LSS in the same patient group while similar to that of the MAP-BE based on the 0/4/8 h LSS developed in liver transplant patients, and (iv) yielded a RMSE similar to that of MAP-BE based on the

Table 2 Performance of different ML algorithms and limited sampling strategies to estimate tacrolimus AUC_{0–24 h} as compared with the reference AUC_{0–24 h}: in the analysis set after tenfold cross-validation; and in the assessment set

ML algorithm dataset	2-sample LSS (0/12 h)				3-sample LSS (0/8/12 h)			
	Relative MPE (%)	Relative RMSE (%)	Number of estimates out of $\pm$ the 20% interval <i>n</i> (%)	Number of estimates out of $\pm$ the 10% interval <i>n</i> (%)	Relative MPE (%)	Relative RMSE (%)	Number of estimates out of $\pm$ the 20% interval <i>n</i> (%)	Number of estimates out of $\pm$ the 10% interval <i>n</i> (%)
GLMNET *Analysis set	1.50	11.0	9 (6.9)	35 (26.9)	0.97	9.36	7 (5.3)	29 (22.3)
GLMNET Assessment set	- 2.9	10.4	2(7.1)	9(32.1)	0.90	10.12	1 (3.6)	5 (17.9)
XGBOOST *Analysis set	2.12	17.6	13 (10.0)	56 (43.1)	0.79	13.1	14 (10.7)	40 (30.8)
XGBOOST Assessment set	- 0.9	11.4	3 (10.7)	10 (35.7)	0.43	9.17	2 (7.1)	8 (28.6)
MARS *Analysis set	1.23	11.1	9 (6.9)	35 (26.9)	0.45	9.8	7 (5.3)	33 (25.3)
MARS Assessment set	- 1.9	10.0	0 (0)	9 (32.1)	- 1.28	7.57	1 (3.6)	6 (21.4)

*Results in the analysis set were obtained after ten-fold cross validation; GLMNET is LASSO and elastic-net regularized generalized linear models, XGBOOST is extreme gradient boosting, and MARS is multivariate adaptive regression splines

Fig. 1 Scatter plot of AUC₀₋₂₄ s estimated using the MARS algorithm based on 2 points at 0 and 12 h (A) or 3 points at 0, 8, and 12 h (B) vs reference trapezoidal AUC₀₋₂₄ in the test set, and corresponding Bland–Altman plots (C and D). Difference is the difference between the reference and the MARS AUC₀₋₂₄ s, and mean is the average of both



0/8/12 h LSS in liver transplant patients and similar bias or number of patient out of the 20% bias range in comparison to the original study [9]. The corresponding Bland–Altman plot of predicted vs reference AUCs is presented in Figs. 3 and 4.

Discussion

The MARS models developed here provide accurate AUC estimation for melt-dose tacrolimus, using only concentrations measured at 0 and 12 h and a very limited number of other features.

The sample at 12 h may be difficult to draw in routine practice, as it is unlikely that outpatients are kept for 12 h at the

hospital. However, as previously observed [8] and shown in the variable importance plot (Fig. 2), it was one of the most important features in our algorithm. Capillary blood microsampling devices may make collection of this late point easier even if it could introduce another source of variability. Indeed, there is an additional bias and imprecision that can vary between the types of device [17–19]. Another MAP-BE developed for liver transplant recipients required a late sample at 8 h to yield accurate AUC estimation [9]. However, the ML algorithms including 8 h instead of 12 h were not associated with better performance in the present study. Interestingly, C8 was the most important time point in the VIP plot, but its combination with C0 led to decreased performances in comparison with the C0 and C12 combination.

Fig. 2 Variable importance plot for the MARS algorithm in the analysis set. “C0” is concentration sampled at $t=0$ min, “C8” is the concentration sampled between 6.6 and 8.5 h, and “C12” is the concentration sampled between 8.6 and 12.5 h. Importance is relative calculated using a generalized cross-validation (GCV) statistic




Table 3 Performance of the final MARS algorithm based on 2 concentrations (0 and 12 h) and 3 concentrations (0, 8, and 12 h) to estimate AUCs in two independent validation sets as compared with previous MAP-BE using 3-point LSSs

		Relative MPE (%)	Relative RMSE (%)	Relative errors out of $\pm 20\%$ <i>n</i> (%)	Relative errors out of $\pm 10\%$ <i>n</i> (%)
Kidney transplant recipients (<i>n</i> = 16)	MARS 0/12 h	−3.1	11.1	2 (12.5%)	5 (31.3%)
	MARS 0/8/12 h	−4.2	10.1	1 (6.3%)	5 (31.3%)
	MAP-BE 0/8/12 h (developed in renal transplant patients) [8]	7.3	23.0	8 (53.3%)	12 (80%)
	MAP-BE 0/4/8 h (developed in liver transplant patients) [9]	−7.4	11.2	1 (6.3%)	7 (43.8%)
Liver transplant recipients (<i>n</i> = 48) [9]	MARS 0/12 h	−3.4	9.86	3 (6.2%)	13 (27.1%)
	MARS 0/8/12 h	−3.4	9.14	2 (4.1%)	12 (25%)
	MAP-BE 0/8/12 h (developed in liver transplant patients) [8]	−1.2	8.84	1 (2.1%)	9 (20.8%)
	MAP-BE 0/4/8 h (developed in the same liver transplant patients) [9]	1.8*	8.64*	0 (0%) (<i>n</i> = 53)*	4 (7.50%) (<i>n</i> = 53)*

AUC is area under the curve, MAP-BE is maximum a posteriori Bayesian estimation, and MARS is multivariate adaptive regression splines

*Corresponds to the results reported in the original study in which the same patients were used to develop the model and evaluate the LSS

We investigated 3 different algorithms that rely on different approaches. GLMNET is a penalized regression and is based on a linear relationship between predictors and AUC, the 2 others are based on nonlinear relationships (Xgboost is an ensemble method that aggregates decision trees and MARS is a non-parametric derived regression that breaks a given distribution into small linear pieces).

In our previous works on machine learning tacrolimus AUC estimation [11], we either used as references 3-point MAP-BE estimates of the AUC or PK profiles simulated using a POPPK model [20]. Here, the reference AUC was calculated for each patient using the trapezoidal rule on rich PK profiles (samples collected pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 20, and 24 h after dosing). We hypothesized that using

complete profiles for model development would decrease the noise and improve estimation performance even if the training set was smaller. Actually, the performances in an external validation set obtained in the present study were similar to and no better than those obtained in the previous studies. However, this is an indirect comparison since the studies were performed for different tacrolimus formulations.

When evaluated in an external dataset of kidney transplant recipients, the ML models developed outperformed the MAP-BEs previously developed on the same datasets. A possible explanation is that some PK profiles in the dataset were not necessarily at steady state, which may mislead mechanistic models more than ML algorithms. Another explanation would be that the patients were quite unusual



Fig. 3 Bland–Altman of reference vs predicted AUC_{0–24} s using MARS algorithm based on points (0/12 h, **A**) or 3 points (0/8/12 h, **B**), and MAP-BE based on 3 points (0/8/12 h (**C**) or 0/4/8 h (**D**)) in the renal transplant patient external dataset

Fig. 4 Bland–Altman of reference vs predicted AUCs using MARS algorithm based on 2 points (0/12 h, **A**) or 3 points (0/8/12 h, **B**), and MAP-BE based on 3 points (0/8/12 h, **C**) in the liver transplant patient external dataset [9]



and that the ML algorithm is more flexible to model them since it is less constrained. On the contrary, for liver transplant recipients, the performances obtained in the same external dataset by a MAP-BE previously developed for this graft type were similar to those of the ML algorithms trained in a dataset of both renal and liver transplant recipients.

When evaluated in liver transplant patients at 2 weeks after the switch (i.e., against the profiles used to develop the POPPK model [9]), the performances of the 2- or 3-sample MARS algorithm and of our MAP-BE previously developed in liver transplant patients [8] were excellent and exhibit bias and number of profile with bias out of the 20% interval similar to the ones reported in the original study [9]. Of note, the performances of the MAP-BE were numerically better than those of the MARS algorithm in the validation dataset. This could be explained by the limited number of samples available for the development of the ML algorithm (data driven approach), whereas the POPPK models (mechanistic approach) require a lower number of samples to provide very accurate results. Recently, we have shown that the addition of simulations from a POPPK model to experimental data could improve the learning performances of ML algorithms [21].

The methodology used in the present study for the development of the model can be regarded as complex since we performed 2 consecutive data splitting. However, this two-set approach allowed us to prevent overfitting and to benchmark different algorithms in the train set while keeping the test set for the final evaluation only.

The range of the time classes was investigated and selected manually in order to have the most patients as possible with all the bins. Even if it was a subjective approach, we think that it has not biased the analysis. For the external validation, we also removed subjectively profiles with sampling time deviation > 5% or 1 h from the theoretical LSS. Interestingly, the

feature “relative deviation with respect to the theoretical sampling time” was not selected as important by the algorithms. Nevertheless, further studies with external data or simulations studies have to be performed to clarify this point.

This study has some limitations. First, pharmacogenetic data were not available. It is well established that the CYP3A5 genotype influences tacrolimus clearance and that patients expressing CYP3A5 require a higher tacrolimus dose than non-expressors; even this influence might be less for Envarsus due to its more distal absorption [9]. Anyway, its implication has not been studied so far in machine learning estimators of tacrolimus AUC, and even without this information the accuracy and precision of the models are excellent. Secondly, the size of the external validation set is small for renal transplant patients, but full PK profiles are not easily available. Finally, all the patients used to develop and validate the algorithm were at a stable transplant period (at least 6 months post transplantation). The performances of the algorithms developed should be further investigated in patients in the early phase post transplantation.

In conclusion, a MARS estimator developed from “true” reference AUCs very accurately estimated melt-dose tacrolimus AUC using only 2 or 3 blood concentrations and a few numbers of other features. It performs as well as ML estimators we previously developed for other tacrolimus formulations, where 3-point LSS and MAP-BE AUCs or trapezoidal AUCs from simulated PK profiles were used as references. The MARS estimator based on two time points may improve the use of AUC-based tacrolimus individual dose adjustment.

Supplementary Information The online version contains supplementary material available at <https://doi.org/10.1007/s00228-022-03445-5>.

Acknowledgements The authors gratefully thank Veloxis and Chiesi for providing the phase II pharmacokinetic data.

Author contribution LP, JBW, DJM, PM, and ML conceived or designed the study. LP, JBW, DJM, CM, LR, and BvH performed the research, LP, JBW, DJM, PM, and ML analyzed the data, LP, PM, DJM, ML, and JBW wrote the paper.

Availability of data and materials The datasets analyzed during the current study are property of Veloxis and Chiesi and are not publicly available.

Declarations

Ethics approval The trials complied with the Declaration of Helsinki amended in Tokyo, and all the patients enrolled gave their written informed consent.

Competing interests Laure Ponthier, Dirk Jan A.R. Moes, Bart van Hoek, Caroline Monchaud, and Marc Labriffe have no conflicts of interest that are relevant to the content of this manuscript. Pierre Marquet and L Rostaing has received research grants and speaker fees from Chiesi, and JB Woillard has received speaker fees from Chiesi.

References

- Brunet M, van Gelder T, Åsberg A, Haufroid V, Hesselink DA, Langman L et al (2019) Therapeutic drug monitoring of tacrolimus-personalized therapy: second consensus report. *Ther Drug Monit* 41:261–307
- Woillard JB, Monchaud C, Saint-Marcoux F, Labriffe M, Marquet P (2022) Can the area under the curve/trough level ratio be used to optimize tacrolimus individual dose adjustment? *Transplantation. Volume-Issue-10.1097*
- Staatz CE, Tett SE (2004) Clinical pharmacokinetics and pharmacodynamics of tacrolimus in solid organ transplantation. *Clin Pharmacokinet* 43:623–653
- Hesselink DA, Bouamar R, Elens L, van Schaik RHN, van Gelder T (2014) The role of pharmacogenetics in the disposition of and response to tacrolimus in solid organ transplantation. *Clin Pharmacokinet* 53:123–139
- Saint-Marcoux F, Woillard J-B, Jurado C, Marquet P (2013) Lessons from routine dose adjustment of tacrolimus in renal transplant patients based on global exposure. *Ther Drug Monit* 35:322–327
- Woillard J-B, Saint-Marcoux F, Debord J, Åsberg A (2018) Pharmacokinetic models to assist the prescriber in choosing the best tacrolimus dose. *Pharmacol Res* 130:316–321
- Bouamar R, Shuker N, Hesselink DA, Weimar W, Ekberg H, Kaplan B et al (2013) Tacrolimus predose concentrations do not predict the risk of acute rejection after renal transplantation: a pooled analysis from three randomized-controlled clinical trials. *Am J Transplant* 13:1253–1261
- Woillard J-B, Debord J, Monchaud C, Saint-Marcoux F, Marquet P (2017) Population pharmacokinetics and Bayesian estimators for refined dose adjustment of a new tacrolimus formulation in kidney and liver transplant patients. *Clin Pharmacokinet* 56:1491–1498
- Martial LC, Biewenga M, Ruijter BN, Keizer R, Swen JJ, van Hoek B et al (2021) Population pharmacokinetics and genetics of oral meldonate tacrolimus (Envarsus) in stable adult liver transplant recipients. *Br J Clin Pharmacol* 87:4262–4272.
- Lima AN, Philot EA, Trossini GHG, Scott LPB, Maltarollo VG, Honorio KM (2016) Use of machine learning approaches for novel drug discovery. *Expert Opin Drug Discov* 11:225–239
- Woillard J-B, Labriffe M, Debord J, Marquet P (2020) Tacrolimus Exposure prediction using machine learning. *Clin Pharmacol Ther* 110:361–369
- Denney WS, Duvvuri S, Buckeridge C (2015) Simple, automatic noncompartmental analysis: the PKNCA R package. *J Pharmacokinet Pharmacodyn*. [cited 2021 May 9];42:11–107. Available from: <http://link.springer.com/10.1007/s10928-015-9432-2>. Accessed 17 Mar 2022
- Kuhn M, Wickham H (2020). Tidymodels: a collection of packages for modeling and machine learning using tidyverse principles. <https://www.tidymodels.org>. Accessed 17 Mar 2022
- Chen T, Guestrin C (2016) XGBoost: A scalable tree boosting system. *Proceedings of the 22nd ACM SIGKDD International Conference on Knowledge Discovery and Data Mining*. San Francisco California USA: ACM; [cited 2021 Jun 30]. p. 785–94. Available from: <https://dl.acm.org/doi/10.1145/2939672.2939785>. Accessed 17 Mar 2022
- Friedman JH, Roosen CB (1995) An introduction to multivariate adaptive regression splines. *Stat Methods Med Res* 4:197–217
- Friedman J, Hastie T, Tibshirani R (2010) Regularization paths for generalized linear models via coordinate descent. *J Stat Softw* 33:1–22
- Deprez S, Stove CP (2021) Fully automated dried blood spot extraction coupled to liquid chromatography-tandem mass spectrometry for therapeutic drug monitoring of immunosuppressants. *J Chromatogr A* 1653:462430
- Capiau S, Veenhof H, Koster RA, Bergqvist Y, Boettcher M, Halmingh O et al (2019) Official International Association for Therapeutic Drug Monitoring and Clinical Toxicology guideline: development and validation of dried blood spot-based methods for therapeutic drug monitoring. *Ther Drug Monit* 41:409–430
- Delahaye L, Veenhof H, Koch BCP, Alffenaar J-WC, Linden R, Stove C (2021) Alternative sampling devices to collect dried blood microsamples: state-of-the-art. *Ther Drug Monit* 43:310–21
- Woillard J-B, Labriffe M, Prémaud A, Marquet P (2021) Estimation of drug exposure by machine learning based on simulations from published pharmacokinetic models: the example of tacrolimus. *Pharmacol Res* 167:105578
- Labriffe M, Woillard J-B, Debord J, Marquet P (2022) Machine learning algorithms to estimate everolimus exposure trained on simulated and patient pharmacokinetic profiles. *CPT Pharmacometrics Syst Pharmacol* 11:1018–1028

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Authors and Affiliations

Laure Ponthier^{1,2} · Pierre Marquet^{1,3} · Dirk Jan A. R. Moes⁴ · Lionel Rostaing⁵ · Bart van Hoek⁶ · Caroline Monchaud^{1,3} · Marc Labriffe^{1,3} · Jean Baptiste Woillard^{1,3} 

✉ Jean Baptiste Woillard
jean-baptiste.woillard@unilim.fr

¹ P&T, Univ. Limoges, INSERM, Limoges, France

² Department of Pediatrics, CHU Limoges, Limoges, France

³ Department of Pharmacology and Toxicology, CHU Limoges, Limoges, France

⁴ Department of Clinical Pharmacy & Toxicology, Leiden University Medical Center, Leiden, The Netherlands

⁵ Nephrology, Hemodialysis, Apheresis and Kidney Transplantation Department, Grenoble University Hospital, Grenoble, and Grenoble Alpes University, Grenoble, France

⁶ Department of Hepatology, Leiden University Medical Center, Leiden, The Netherlands